Latest News
Breakthroughs, partnerships, and milestones from Australia's leading biologics research facility.
Research & Impact
The National Biologics Facility plays a pivotal role in translating Australian research into real-world therapies. From recombinant protein production and antibody discovery through to Phase I clinical manufacturing, NBF partners with university researchers, biotech startups, and established pharmaceutical companies to advance biologics from bench to bedside. Our work spans vaccine development, therapeutic antibody engineering, antibody-drug conjugates, and novel biopharmaceutical platforms, supporting projects that address some of the most pressing health challenges in oncology, infectious disease, and beyond. Explore the latest breakthroughs, partnerships, and milestones from our team at the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland.
PEF and NBF Unite Under One Banner
Two of Australia's leading protein and biologics facilities at AIBN are coming together under the NBF banner, creating an end-to-end capability from early-stage recombinant protein production through to clinical-grade biologic manufacturing.
Read full article
Heart Hope as Potential Funnel-Web Venom Drug Enters Clinical Trial
A potential treatment for heart attack and stroke, derived from a spider venom molecule identified by University of Queensland researchers, has been administered to the first participants in a clinical trial.
Read more
UQ Scientific Excellence Reaches the Global Pipeline in Landmark Deal
One of the world's leading healthcare companies has completed its acquisition of the biopharmaceutical company commercialising UQ's Molecular Clamp technology.
Read more
Researchers Build New Antibody to Target Cancer Cells
A cancer-targeting antibody that helps the body's immune cells spot and destroy hard-to-treat tumours such as triple-negative breast cancer has been developed.
Read more
Australian Ovarian Cancer Breakthrough Enters Human Trials
National research facilities including the NBF have supported development of a promising new ovarian cancer drug from early-stage development through to first-in-human studies.
Read more
100-Day Challenge to Develop World-First Chapare Virus Vaccine
UQ researchers are working to develop a vaccine in just 100 days to support future pandemic preparedness, with clinical-grade batch production at the NBF.
Read more
ViceBio and the Rapid Response Vaccine Pipeline
The AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever and wherever they are needed.
Read more
UQ Secures Global Partnership to Create Homegrown Lifesaving Vaccines
A $32 million partnership between UQ and Emory University will establish the Queensland Emory Vaccine Centre to accelerate vaccine development.
Read more
Accelerating the Pipeline of Antiviral Biologics for Pandemic Preparedness
NBF is working with Dr Adam Wheatley and team from the Doherty Institute, awarded $1.5M in funding for antiviral drug discovery and validation.
Read more
Advancing Pandemic Preparedness with Novel Therapeutic Platform
Researchers at the Doherty Institute, with collaborators from NBF and Biointelect, are developing a novel therapeutic platform to combat viral pathogens.
Read more
Clamp2 Provides Vaccine Hope for Future Pandemics
UQ is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial, with the clinical batch manufactured at the NBF.
Read more
NBF Nodes Collaborate to Support Phase I COVID-19 Vaccine
The first participants in the clinical trial of two Melbourne-made COVID-19 vaccines have been safely administered their doses.
Read more
New Role Looks at Worm Saliva to Eradicate Diabetes
AIBN Professor Trent Munro and the NBF team have conducted collaborative research to develop potentially game-changing therapeutics for Type 2 diabetes.
Read more
